<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521363</url>
  </required_header>
  <id_info>
    <org_study_id>15-127</org_study_id>
    <nct_id>NCT02521363</nct_id>
  </id_info>
  <brief_title>Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer</brief_title>
  <official_title>Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and feasibility of placing and removing a
      small device that contains anti-cancer drugs in a breast tumor of patients who plan on having
      breast surgery without treatment prior or patients who plan on receiving standard
      preoperative chemotherapy prior to their breast surgery. This device may be able to predict
      what types of treatment work best against an individual's breast cancer. With this device,
      the investigators hope to be able to personalize treatment choices based on an individual's
      type of breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of implantable devices</measure>
    <time_frame>1 year</time_frame>
    <description>If we are able to collect data from at least 6 out of the 12 patients, we will deem this study feasible to conduct in a larger cohort of patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Upfront Breast Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will have the microdevice implanted prior to breast surgery, in the absence of neoadjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will have the device placed and retrieved on a core biopsy the following day, then receive neoadjuvant chemotherapy prior to definitive breast surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KIBUR MICRODEVICE</intervention_name>
    <description>This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for ~24 hours.</description>
    <arm_group_label>Upfront Breast Surgery</arm_group_label>
    <arm_group_label>Neoadjuvant Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anthracycline and taxane based chemotherapy</intervention_name>
    <description>Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout</description>
    <arm_group_label>Neoadjuvant Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed invasive breast cancer that is: Triple negative
             (ER&lt;10%, PR&lt;10%, and HER2 0/1+ or 2+/FISH not amplified)

          -  Tumor size 2cm or greater; N any; M0

          -  Tumor size 1cm or greater; N any; M0 (Cohort 1)

          -  Tumor size 2cm or greater; N any; M0 (Cohort 2)

          -  Candidate for curative breast cancer surgery (Cohort 1 or 2)

          -  Candidate for neoadjuvant chemotherapy with a standard of care, anthracycline-based
             regimen (Cohort 2 preferred over Cohort 1)

          -  Age &gt;18 years of age

          -  ECOG performance status of â‰¤2

          -  Serum or urine pregnancy test negative within 2 weeks for women of childbearing
             potential.

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Prior treatment including surgery, chemotherapy or radiation therapy for the current
             primary breast cancer.

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality
             that may increase the risk associated with study participation or investigational
             device administration or may interfere with the interpretation of study results and,
             in the judgment of the investigator, would make the patient inappropriate for entry
             into this
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiffany Traina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffany Traina, MD</last_name>
    <phone>646-888-5209</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George Plitas, MD</last_name>
    <phone>646-888-4587</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Traina, MD</last_name>
      <phone>646-888-5209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Traina, MD</last_name>
      <phone>646-888-5209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Traina, MD</last_name>
      <phone>646-888-5209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Traina, MD</last_name>
      <phone>646-888-5209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany A. Traina, MD</last_name>
      <phone>646-888-5209</phone>
    </contact>
    <contact_backup>
      <last_name>George Plitas, MD</last_name>
      <phone>646-888-4587</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Traina, MD</last_name>
      <phone>646-888-5209</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Implantable Microdevice</keyword>
  <keyword>In Vivo Drug Sensitivity Testing</keyword>
  <keyword>HER2-Positive</keyword>
  <keyword>Triple Negative</keyword>
  <keyword>15-127</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

